product name Benazepril HCl
Description: Benazepril HCl (also known as CGS 14824A HCl) is a novel angiotensin I converting enzyme inhibitor used primarily in treatment of hypertension. The mechanism of action of thie drug is to prevent the catalytic conversion of angiotensin I to angiotensin II and in turn causes vasodilation and an increase in capillary blood volume. Benazepril hydrochloride dose-dependently inhibits the increase in the blood pressure caused by continuous norepinephrine infusion in spontaneously hypertensive rats and suppresses in seizures.
References: Arzneimittelforschung. 1991 Jun;41(6):602-7; J Vet Med Sci. 2007 Oct;69(10):1015-23.
460.95
Formula
C24H28N2O5.HCl
CAS No.
86541-74-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 92 mg/mL (199.6 mM)
Water: 19 mg/mL (41.2 mM)
Ethanol: 92 mg/mL (199.6 mM)
Solubility (In vivo)
Synonyms
CGS 14824A HCl
other peoduct :
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Benazepril hydrochloride (3 or 10 mg/kg/d, p.o. for 14 days) dose-dependently inhibits the increase in the blood pressure caused by continuous norepinephrine (NE) infusion in spontaneously hypertensive rats (SHR) and suppresses in seizures induced by a monoamine oxidase inhibitor, tranylcypromine in NE infused SHR. Benazepril hydrochloride (30 mg/kg p.o.) decreases the triglyceride and total cholesterol levels in normotensive rats. Benazepril hydrochloride (3 mg/kg s.c.) causes a significant decrease in aortic atherosclerosis without reducing hypercholesterolemia in cholesterol-fed rabbits. Benazepril hydrochloride (100 mg/kg p.o.) shows no effect on the urine volume and urinary excretion of electrolytes but decreases PSP excretion in normotensive rats. Benazepril hydrochloride (10 mg/kg p.o.) inhibits the increase in the excretion of urinary protein in DOCA/salt spontaneously hypertensive rats. Benazepril Hydrochloride administration corrects systemic hypertension and significantly reduces angiotensin II and aldosterone in cats with experimentally induced or spontaneously occurring chronic renal failure. Benazepril hydrochloride administration reduces serum creatinine and urinary protein concentration in cat with experimentally induced or spontaneously occurring chronic renal failure. Benazepril hydrochloride significantly decreases blood pressure, angiotensin II and aldosterone and, increases upon discontinuation of administration to the pre-administration levels in a canine remnant kidney model of chronic renal failure. |
| Animal model | |
| Formulation & Dosage | |
| References | Arzneimittelforschung. 1991 Jun;41(6):602-7; J Vet Med Sci. 2007 Oct;69(10):1015-23. |
